# Medifast Q4 2022 Earnings Presentation

© 2023 Medifast, Inc. All Rights Reserved.

MEDIFAST. MEDIFAST.

## Safe Harbor Statement

Please Note: This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend," "anticipate," "expect" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals, outlook or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of the management of Medifast and are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, risks associated with Medifast's direct-to-consumer business model; the impact of rapid growth on Medifast's systems; disruptions in Medifast's supply chain; Medifast's inability to continue to develop new products; effectiveness of Medifast's advertising and marketing programs, including use of social media by independent OPTAVIA Coaches; Medifast's inability to maintain and grow the network of independent OPTAVIA Coaches; the departure of one or more key personnel; Medifast's inability to protect against online security risks and cyberattacks; to protect its brand and intellectual property, or to protect against product liability claims; Medifast's planned growth into domestic and international markets; adverse publicity associated with Medifast's products; Medifast's inability to continue declaring dividends; fluctuations of Medifast's common stock market price; the prolonged effects of COVID-19 on consumer spending and disruptions to our distribution network, supply chains and operations; increases in competition or litigation; the consequences of other geopolitical events, including natural disasters, global health crises, acts of war (including the war in Ukraine), changes in trade policies and tariffs, climate change, regulatory changes, increases in costs of raw materials, fuel, or other energy, transportation, or utility costs and in the costs of labor and employment, labor shortages, supply chain issues and the resulting impact on market conditions and consumer sentiment and spending; and Medifast's ability to prevent or detect a failure of internal control over financial reporting. Although Medifast believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this presentation, as well as those set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and other filings filed with the United States Securities and Exchange Commission, including its quarterly reports on Form 10-Q and current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this presentation.

eaning of the Private Securities Litigation Reform Act of



## Medifast Q4 2022 Highlights



Q4 2022 Revenue and EPS above highend of guidance range

Operating cash flows improved by 106%

Debt free as of December 31, 2022

Customer retention levels remained at historical norms even with November 2022 price increase

© 2023 Medifast, Inc. All Rights Reserved.



## Medifast By The Numbers: Q4 2022





\$33M / \$53M **GAAP / Non-GAAP**<sup>1</sup> **OPERATING INCOME** 





<sup>1</sup> Refer to the Reconciliation of Selected GAAP Measures on the Q4 Earnings Release on the Company's Investor Relations website at https://ir.medifastinc.com/

© 2023 Medifast, Inc. All Rights Reserved.




#### **GAAP / Non-GAAP<sup>1</sup> EPS**



#### **CASH & CASH EQUIVALENTS**



## Medifast Key Initiatives & Outlook for 2023



Customer acquisition remains a key focus



Margin enhancement program will optimize investments to drive further growth over next three years Long-term focus on enterprise value investments and return of capital

© 2023 Medifast, Inc. All Rights Reserved.



## Q1 2023 Guidance

REVENUE

EPS

## \$300-320M

\$1.75-2.40


© 2023 Medifast, Inc. All Rights Reserved.

TAX RATE

# 2.40 26.00-27.00%



# **Customer Acquisition Initiatives**



### Programming

Implement enhanced programs, such as **Commit to** Health, to help:

- Coaches attract & engage new Customers
- Incentivize repeat orders
- Increase long-term retention

### **Coach Support/Training**

Offer an enriched training & development curriculum, including Coach Bootcamps, to support:

- New/existing Coaches build their business
- Drive engagement & encourage growth

© 2023 Medifast, Inc. All Rights Reserved.





### Offer


Innovate/expand digital products & offerings to enhance the OPTAVIA experience via:

- Enhanced tools that aid • Customers on their wellness journey
- Tech support that improves • Coach productivity









### \$378M

2020-2022 **FREE CASH FLOW** 



## **\$189M**

2020-2022 **DIVIDENDS** 

**\$187M** 2020-2022 **STOCK BUYBACKS** 



© 2023 Medifast, Inc. All Rights Reserved.

### 2023 and Beyond Maintain sufficient cash balance for organic growth 2 Maintain and continue to grow dividend **Consistently apply excess funds to stock** 3 repurchases Maintain a conservative balance sheet with a low amount of leverage

